Paul Silva - Vertex Pharmaceuticals Senior Vice President Corporate Controller

VRTX -- USA Stock  

USD 176.14  1.62  0.93%

  President
Mr. Paul M. Silva is Senior Vice President, Controller of the company, and he is no longer as Interim Chief Financial Officer, Effective April 10, 2019. Mr. Silva is our Senior Vice President and Corporationrationrate Controller, a position he has held since April 2011. Mr. Silva joined us in August 2007 as Senior Director, Accounting Operations and was our Vice President and Corporationrationrate Controller from September 2008 through April 2011. Prior to joining us, he was the Vice President, Internal Reporting at Iron Mountain Incorporated from July 2006 until August 2007 and a consultant to Iron Mountains financing department from April 2005 until July 2006. He was the Finance Director of the Bioscience Technologies Division of Thermo Electron Corporationrationration from 2002 to April 2005
Age: 51  President Since 2019      
617-341-6100  http://www.vrtx.com
Silva holds a B.S. in accounting from Assumption College.

Paul Silva Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Cartikeya ReddyDr Reddys Laboratories Ltd
2016
Daniel PlewRegeneron Pharmaceuticals
2016
John HendricksonPerrigo Company plc
2016
Alok SonigDr Reddys Laboratories Ltd
2015
Paul WeningerPerrigo Company plc
2015
Roman TrawickiZoetis
2015
Ronald JanishPerrigo Company plc
2015
Glenn DavidZoetis
2016
James MichaudPerrigo Company plc
2016
Sandra BeatyZoetis
2012
K RaoDr Reddys Laboratories Ltd
2016
Christopher FenimoreRegeneron Pharmaceuticals
2017
John WesolowskiPerrigo Company plc
2016
Joyce LeeZoetis
2012
Clinton LewisZoetis
2018
Michael AbermanRegeneron Pharmaceuticals
2015
J RamachandranDr Reddys Laboratories Ltd
2016
Peter PowchikRegeneron Pharmaceuticals
2006
Marc CouckePerrigo Company plc
N/A
Heidi ChenZoetis
2012
Scott JamisonPerrigo Company plc
2011

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Portfolio Reporting Now

   

Portfolio Reporting

Create custom reports across your portfolios and generate quick suggestion pitch
All  Next Launch Module

Also Currentnly Active

Purchased few shares of
few hours ago
Traded for 188.14
Purchased a lot of shares of
few hours ago
Traded for 150.35
Purchased few shares of
few hours ago
Traded for 175.29
Also please take a look at World Market Map. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Search macroaxis.com